BRAVECTO® TriUNO chewable tablets for dogs
Bravecto TriUNO is the newest addition to the Bravecto family, protecting dogs from 8 weeks of age against fleas, ticks and common worms in a monthly chewable tablet.
Bravecto TriUNO provides a perfect start for puppies into the Bravecto family, moving to
Bravecto long-duration options from 6 months of age for tailored year-round protection.
Presentation
Light pink to light brown coloured, mottled, round-shaped chewable tablets.
Active ingredients
| BRAVECTO TriUNO chewable tablets for dogs |
Fluralaner (mg) |
Moxidectin (mg) | Pyrantel (as embonate) (mg) |
| 1.27–2.5 kg | 25 | 0.0625 | 12.5 |
| > 2.5–5 kg | 50 | 0.125 | 25 |
| > 5–10 kg | 100 | 0.25 | 50 |
| > 10–20 kg | 200 | 0.5 | 100 |
| > 20–40 kg | 400 | 1 | 200 |
| > 40–60 kg | 600 | 1.5 | 300 |
Target species
Dogs
Indications for use
For dogs with, or at risk from, mixed parasitic infestations by ticks or fleas, gastrointestinal nematodes, lungworm and/or heartworm. The veterinary medicinal product is exclusively indicated when use against ticks or fleas, one or more of the target gastrointestinal nematodes, and prevention of either heartworm or lungworm disease, are all indicated at the same time.
For the treatment of tick and flea infestations on dogs providing immediate and persistent flea (Ctenocephalides felis and C. canis) and tick (Dermacentor reticulatus, Ixodes hexagonus, I. ricinus, and Rhipicephalus sanguineus) killing activity for 1 month.
The veterinary medicinal product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
For reduction of the risk of infection with Babesia canis canis via transmission by D. reticulatus for 1 month. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
For reduction of the risk of infection with Dipylidium caninum via transmission by C. felis for 1 month. The effect is indirect due to the veterinary medicinal product’s activity against the vector.
Treatment of infections with gastrointestinal nematodes of the following species:
roundworms (adult stages of Toxocara canis and Toxascaris leonina), hookworms (L4, immature adult (L5) and adult stages of Ancylostoma caninum and adult stages of Uncinaria stenocephala).
Prevention of heartworm disease (caused by Dirofilaria immitis).
Prevention of angiostrongylosis (by reduction of the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum).
Bravecto TriUNO dogs can be used from 8 weeks of age and 1.27 kg in bodyweight.
Packaging
Carton with aluminium foil blister sealed with PET aluminium foil lid stock.
One cardboard box contains 1, 3 or 6 chewable tablets.
Not all pack sizes may be marketed.
Legal Category
POM-V
Further information is available from the SPC, datasheet or package leaflet.
Advice should be sought from the medicine prescriber.
Prescription decisions are for the person issuing the prescription alone.
Use Medicines Responsibly.
Product images are representations of packaging and may not accurately reflect the current packaging available in the GB marketplace.
Date of preparation: May 2025